Aurelia Caparos
Leiden, Netherlands, April 19, 2024 – Amarna Therapeuticsa privately held biotechnology company developing transformative gene therapies for a variety of rare and epidemic diseases, including type 1 diabetes, today names Aurelia Caparros as the company's new chief business officer (CBO). I announced what I had done.cent April 2024.
Aurelia has over 25 years of experience in the healthcare industry with expertise in business development, strategy, and global marketing including P&L responsibility across various geographies. She has held global leadership roles at companies including Novartis, where she led multiple corporate transformation programs and implemented strategic growth initiatives to achieve business goals while fostering a culture and mindset of inclusion. In her new role as CBO, she will be responsible for driving Amarna's future growth and expansion in both the Netherlands and Spain.
Her primary responsibilities include identifying assets, companies, and areas of interest, designing customized partnership structures, and securing attractive deals throughout the transaction process. Aurelia will also play a key role in promoting Amarna as a partner of choice at business partner conferences and academic conferences, as well as supporting Amarna's investor relations and fundraising efforts. .
“We are very pleased to welcome Aurelia Caparros as our new Chief Business Officer.” Henk Striefkerk, Chief Executive Officer and Medical Director of Amarna Therapeutics BV said: “Her outstanding leadership and deep industry expertise will be invaluable as we continue to expand our business and bring innovative gene therapies to patients in need. ”
=== End ===
About Amarna
Amaruna Therapeutics has developed an innovative non-immunogenic viral platform for delivering arbitrary transgenes to humans. The company is advancing a pipeline of transformative gene therapies for a variety of rare and prevalent diseases, including single-gene indications, autoimmune diseases, and chronic inflammation. Key Program Nimvec™ AM510 is being developed for the treatment of patients with type 1 diabetes. Follow-up programs include multiple sclerosis, age-related macular degeneration, and hemophilia.
About type 1 diabetes
Type 1 diabetes is a debilitating disease that affects millions of people worldwide, its incidence is increasing yearly, and despite advances in treatment, life expectancy is decreasing. It remains lower than the general population. Diabetes is an autoimmune disease in which autoreactive T lymphocytes selectively attack and destroy insulin-producing beta cells in the pancreas, leaving patients unable to maintain glucose homeostasis. Proinsulin (PI) is a major autoantigen involved in autoimmune β-cell destruction. To date, type 1 diabetes cannot be cured, but glucose homeostasis in patients can be more or less maintained with daily insulin injections. Although diabetes is now considered a manageable disease, current treatments have many secondary complications that lead to significant morbidity and mortality. Using Nimvec™ AM510, we aim to restore immune tolerance to proinsulin and potentially cure patients.
For more information, www.amarnatherapeutics.com
Follow us on LinkedIn
https://www.linkedin.com/company/amarna-therapeutics-bv.
If you have any further inquiries, please contact us below.
Amarna Therapeutics
Henk Striefkerk, CEO
Email: info@amarnatherapeutics.com
LifeSpring Life Science Communication, Amsterdam
Leon Melance
Phone: +31 6 538 16 427
Email: lmelens@lifespring.nl
Aurelia Caparrós, new CEO of Amarna Therapeutics (Leiden, Netherlands)
attachment